
VYLOY is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.
When used in combination with other antineoplastic therapeutic agents, the recommended first dose for adult patients is 800 mg/m², and the dose from the second administration onwards may be reduced to 600 mg/m².
Zolbetuximab has demonstrated significant therapeutic potential in the treatment of malignant tumors such as gastric...
Zolbetuximab has demonstrated significant therapeutic potential in the treatment of malignant tumors such as gastric...
As an IgG1 monoclonal antibody targeting Claudin 18.2 (CLDN18.2), zolbetuximab plays a crucial role in the treatment...
Zolbetuximab is a targeted therapeutic drug directed against CLDN18.2, and it has attracted significant attention in...
Zolbetuximab is a targeted therapeutic drug against CLDN18.2, which plays a crucial role in the treatment of...
Zolbetuximab demonstrates favorable efficacy in the treatment of unresectable advanced recurrent gastric cancer...